ChIP-ing Away at a Proteomics Bottleneck

Courtesy of Andrew Gooley, Proteome Systems Among proteomics techniques, protein microarrays may be getting a lot of buzz these days, but two-dimensional gels still do most of the work. That's because protein arrays present a number of technical challenges that have limited their implementation.1 Proteins vary wildly in stability, solubility, viscosity, and ease of synthesis, for instance. And, the in vitro translated proteins generally used to construct protein biochips often lack the wide d

Written byJeffrey Perkel
| 4 min read

Register for free to listen to this article
Listen with Speechify
0:00
4:00
Share

Among proteomics techniques, protein microarrays may be getting a lot of buzz these days, but two-dimensional gels still do most of the work. That's because protein arrays present a number of technical challenges that have limited their implementation.1 Proteins vary wildly in stability, solubility, viscosity, and ease of synthesis, for instance. And, the in vitro translated proteins generally used to construct protein biochips often lack the wide diversity of co- and post-translational modifications that can affect protein activity in vivo.

But protein arrays aren't dead in the water. Recently, Andrew Gooley, chief scientific officer at Proteome Systems, New South Wales, Australia, and colleagues asserted that the product of two-dimensional gel electrophoresis is basically a protein array.2 The difference between such an array and traditional microarrays, the authors explained in their manuscript, is that each protein's position is defined not by the user, but by its isoelectric point and molecular weight.

...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies